A high-loaded dosage form (HLDF) architecture was developed to address the challenge of large dosage form size or number of units for amorphous solid dispersions (ASDs). The HLDF platform can reduce tablet mass by at least 40% while maintaining performance, stability and manufacturability.
By attending this webinar gain an understanding of how to combine two different polymers, one “inside” and one “outside” the ASD to maximize performance, physical stability, and drug loading of ASD drug products.